

LakePharma Protein Engineering Symposium

Friday, October 6th, 2017

So. San Francisco Conference Center

Agenda

8:30 am **Breakfast and Registration**

8:55 am **Welcome Remarks**

Morning Session I: Protein Engineering and Biotechnology

- 9:00 – 9:30 am • Patrick Y. Yang, Ph.D., Chairman, Acepodia & Executive Vice President, Juno Therapeutics
"The trend and future of the biotech industry"
- 9:35 – 10:05 am • Arvind Rajpal, Ph.D., Vice President, BMS, Protein Therapeutics
"Protein engineering in oncology"

10:10 – 10:40 am **Morning Break in Exhibition Area**

Morning Session II: ADCs and Bispecifics

- 10:40 – 11:10 am • Scott Dylla, Ph.D., Vice President of Research & Development, CSO, Abbvie Stemcentrx
"Preclinical modeling and screening strategies to improve the clinical translation of ADCs"
- 11:15 – 11:45 am • Christoph Spiess, Ph.D., Senior Scientist, Genentech
"Bispecific antibodies: strategies, considerations and challenges"

11:50 am – 1:00 pm **Lunch break**

12:30 – 1:00 pm

Breakout Sessions: In Salons A - D

Henry Chiou, Ph.D., Portfolio Leader for Protein Expression at Thermo Fisher
"Latest development in high titer protein expression using ExpiCHO transient expression"

Aaron Sato, Ph.D., CSO, LakePharma
"The LakePharma Antibody Technology Network (LATN) – an introduction to using LATN to access top antibody technologies and resources"

Jamison Grailer, Ph.D., Senior Research Scientist, Promega
"Promega's expanding suite of bioassays for biologics"

Michael Benzinou, Co-Founder & SVP, Nanomolar
"Nanomolar—a disruptive marketplace platform connecting technology with investors"

Afternoon Session I: Antibody Discovery

- 1:05 pm • John "Lippy" Lippincott, Ph.D., VP of Antibody Discovery, LakePharma
Brief remarks
- 1:10 – 1:40 pm • Jacob Glanville, Ph.D., CSO, Distributed Bio
"SuperHuman-2.0: how computational immunoengineering can realize the dream of a one-week antibody discovery cycle"
- 1:45 – 2:15 pm • Andy Yeung, Ph.D., Associate Research Fellow, Pfizer-Rinat
"Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire"

2:20 – 3:00 pm **Afternoon Break and Poster Session**

Afternoon Session II: Novel Targets and Therapeutic Modalities

- 3:10 – 3:40 pm • Bin Liu, Ph.D., Professor, Department of Anesthesia, UCSF
"Cell surface target selection in antibody therapy development"
- 3:45 – 4:15 pm • Bruce Keyt, Ph.D., CSO, IgM Biosciences
"High avidity, bi-specific IgMs for cross-linking tumor targets in the treatment of cancers"

4:30 – 6:00 pm **Networking & Happy Hour**



LakePharma Protein Engineering Symposium

Friday, October 6th, 2017

So. San Francisco Conference Center

Speaker & Presenter Biographies

Patrick Y. Yang, Ph.D.

Chairman, Acepodia & Executive Vice President, Juno Therapeutics

Dr. Yang has over 35 years leadership experience in technology, manufacturing, supply chain, and operational management functions at General Electric, Merck, Genentech and Roche. He previously was Executive Vice President and Global Head of Roche Pharmaceuticals Technical Operations. He also served as Executive Vice President of Product Operations of Genentech for 10 years. Prior to joining Genentech, Dr. Yang spent 11 years at Merck & Co. as Vice President, Supply Chain Management, and Vice President, Asia/Pacific Operations. Before joining Merck in 1992, Dr. Yang spent 12 years at General Electric serving in research, engineering, technology, and manufacturing leadership roles. Dr. Yang holds a Ph.D. degree in engineering from Ohio State University, Columbus, Ohio and is a member of the Board of Directors of Tesoro Corporation, Codexis, Celladon, Amyris, and PharmaEssentia.

Arvind Rajpal, Ph.D.,

Vice President of Protein Therapeutics, BMS

Dr. Rajpal leads the Protein Therapeutics group at Bristol-Myers Squibb (BMS) in Redwood City. He has more than fifteen years' experience in antibody engineering and biochemistry. He received his B.A. from Knox College in Chemistry and Computer Science, Ph.D. from the University of California at Berkeley in Chemistry, and postdoctoral studies at Pfizer Inc. and University of California at Berkeley in Immunology. Prior to BMS he led a protein engineering group at Rinat-Pfizer where his group pioneered antibody repertoire analysis, developed site-specific conjugation, bispecific IgG, and pH-switch technologies highlighted in numerous publications. At BMS, he is responsible for establishing protein engineering to generate effective and differentiated clinical candidates in oncology.

Scott Dylla, Ph.D.

Vice President of Research & Development & Chief Scientific Officer, AbbVie Stemcentrx

Dr. Dylla co-founded Stemcentrx, Inc., in 2008 and currently serves as a VP of R&D, Chief Scientific Officer of AbbVie Stemcentrx LLC, a wholly owned entity of AbbVie. Dr. Dylla is responsible for overseeing AbbVie Stemcentrx's research and development activities. He received a Bachelor's Degree in Biochemistry and Molecular Biology from the University of Minnesota-Duluth, a Master's Degree in Basic Biomedical Sciences with an emphasis on Molecular Pathobiology from the University of Alabama-Birmingham and a Ph.D. in Cancer Biology and Immunology from the University of Minnesota. He trained as a postdoctoral scholar at Stanford University in the laboratory of Dr. Irving L. Weissman, where he was awarded American Cancer Society and Stanford Immunology fellowships and was subsequently a Sr. Scientist at OncoMed Pharmaceuticals. In 2005, Dr. Dylla was recognized by the British Council as one of eight outstanding young US-based researchers in the field of stem cell biology.

Christoph Spiess, Ph.D.

Senior Scientist, Antibody Engineering, Genentech

Dr. Spiess joined Genentech in 2007 and is currently a senior scientist in the Department of Antibody Engineering. His group is involved in the development of bispecific antibodies for a variety of therapeutic areas as well as in the engineering of antibodies for improved expression and delivery. His group has established new technologies to advance bispecific antibodies from research into Early or Clinical Development in a variety of disease indications. Dr. Spiess received his Ph.D. from the University of Konstanz in Germany. He completed his postdoctoral studies in the field of protein folding at Stanford University before joining Genentech.



LakePharma Protein Engineering Symposium

Friday, October 6th, 2017

So. San Francisco Conference Center

Speaker & Presenter Biographies Cont.

Jacob Glanville, Ph.D.

Chief Scientific Officer, Distributed Bio

Dr. Glanville is a field leader in antibody, TCR and pMHC repertoire algorithms and methods development, having published multiple early defining manuscripts and patents to combine next generation sequencing, protein engineering, immunology, and algorithm development to interrogate antibody repertoires and optimize their responses towards therapeutic applications. He is the co-founder of Distributed Bio and serves as the Chief Scientific Officer. Dr. Glanville completed his undergraduate studies in Genetics, Genomics and Development research at UC Berkeley, served as a Principal Scientist at Pfizer, and earned a Ph.D. in Computational and Systems Immunology at Stanford University School of Medicine.

Andy Yeung, Ph.D.

Associate Research Fellow, Rinat-Pfizer

Andy Yeung is currently an Associate Research Fellow in the Department of Protein Engineering at Rinat laboratory, Oncology R&D, Pfizer Inc. After receiving his B.S. in chemical engineering from the University of Wisconsin-Madison, he carried out his graduate work in the lab of Prof. Dane Wittrup, graduating with a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology. He then completed his postdoctoral research study in the Department of Antibody Engineering at Genentech Inc under the guidance of Dr. Henry Lowman. He has worked at Pfizer-Rinat since 2009. His research group focuses on antibody generation, design, engineering and optimization. He has led protein engineering efforts in disease areas like ophthalmology, metabolic disease, infectious disease, and oncology (T-cell redirected therapy), with the current focus on cancer immunotherapy.

Bin Liu, Ph.D.

Professor, UCSF

Dr. Liu is globally recognized for his research in antibody-based cancer therapeutics. He is a professor at University of California, San Francisco and the principle investigator at the Helen Diller Family Comprehensive Cancer Center at UCSF. His discovery of a unique approach to treating prostate cancer and multiple myeloma led to the creation in 2016 of biopharmaceutical company Fortis Therapeutics. Dr. Liu is highly involved in the national cancer therapeutics community, serving as a member of the UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative, the Sean Parker Institute for Cancer Immunotherapy and other organizations. He holds a B.A. in Molecular Biology and Biochemical Sciences from Princeton University and a doctorate in Biochemistry and Biophysics from UCSF. He is the recipient of more than a dozen scientific honors and has authored more than 20 articles in peer-reviewed journals.

Bruce Keyt, Ph.D.

Chief Scientific Officer, IGM BioSciences

Dr. Keyt brings to IGM more than thirty-five years of research, development and management experience in large and small biotechnology companies, including his extensive experience in many phases of early stage drug discovery and development. Before joining IGM, Dr. Keyt spent 16 years at Genentech, contributing to the development of five marketed products. After receiving his Ph.D. in biochemistry and pharmacology from Tufts University School of Medicine and his B.S. in Chemistry from Washington University in St Louis Dr. Keyt served as director of pharmacology at Millennium Biotherapeutics, Vice President of Preclinical Development at Abgenix and Chief Scientific Officer at Trellis Biosciences. He is the co-inventor on more than 35 U.S. Patents and patent applications and has co-authored more than 55 scientific articles.



LakePharma Protein Engineering Symposium

Friday, October 6th, 2017

So. San Francisco Conference Center

Poster Session

2:20 PM – 3:00 PM

Meeting the Challenges of Antibody Drug Conjugate Characterization by LC-MS/(MS)

Jing Li, Yuzhuo Zhang, Andrew Hanneman, Mario DiPaola

Charles River Laboratories

Discovery of rabbit monoclonal antibodies directly from serum

Stefano Bonissone and Natalie Castellana

Digital Proteomics

SuperHuman 2.0: Computationally Optimized Library Design with Superior Scaffolds and Diversity

Devanshi Shanghavi, David Maurer, Casey Keyes, Sarah Ives, Christina Pettus, Raymond Newland, Chris Smith, Giles Day, Lauren Schwimmer, Jacob Glanville

Distributed Bio

High-Resolution in silico Protein Structure Prediction and Docking

Steven Darnell, PhD, Frederick Blattner, PhD, Brian Anderson, Hosung Shin, Amanda Mitchell, PhD, Matthew Larsen, PhD, Richard Nelson, PhD, Pavel Pinkas, PhD, Adam Briska

DNASTAR, Inc.

LakePharma's CHO GSN Platform

Silka Cheng, Faneng Sun, Jinyan Tang, Lauren Sagara, Hua Tu and Fan Chen

LakePharma, Inc.

Implementing Developability Assessment Platform on Bispecific Antibodies

Jingxing Li, Tyler Chuang, Yong Wang, Kexin Huang

LakePharma, Inc.

Identification of a host cell protein Contaminant in a vaccine antigen and Production for ELISA Development

Norman Garceau, William Hermans, Patrick Cushing, Jason Pratt

LakePharma, Inc.

The Development of a Next Generation Antibody Drug Conjugate

Xuejing Yao, Hongwen Li, Hui Ye, Lele Li, Bethanne Deuel, Andrew C. Huang, Jianmin Fang

MabPlex International



LakePharma Protein Engineering Symposium

Friday, October 6th, 2017
So. San Francisco Conference Center

Poster Session, Cont.

2:20 PM – 3:00 PM

Quantitative cell-based bioassays to advance individual or combination immune checkpoint immunotherapy

Jamison Grailer, Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng

Promega Corporation

Rapid purification and characterization of recombinant proteins and antibodies: Capturem high-capacity membranes

Gia Jokhadze, Nitin Patel, Michael T. Vierra, Boris Levitan, Andrew A. Farmer

Takara Bio

A Novel T-Cell Engaging Bispecific Antibody Platform: Maximizing Tumor Cell Cytotoxicity While Minimizing Cytokine Release

Katherine Harris, Nathan Trinklein, Shelley Force Aldred, Ute Schellenberger, Laura Davison, Heather Ogana, Starlynn Clarke, Kevin Dang, Duy Pham, Payal Pratap, Harshad Ugamraj, Omid Vafa, and Wim van Schooten

TeneoBio

UniRat™ – A Human V_H Discovery Platform for the Generation of Bispecific and Multivalent Antibodies

Harshad Ugamraj, Payal Pratap, Ute Schellenberger, Brett Jorgensen, Shelley Force Aldred, Starlynn Clarke, Kat Harris Kevin Dang, Duy Pham, Nathan Trinklein, Wim van Schooten

TeneoBio

Multispecific Antibodies Targeting CD38 Show Potent Tumor-Specific Cytotoxicity

Starlynn Clarke, Kevin Dang, Shelley Force Aldred, Andrew Boudreau, Ben Buelow, Laura Davison, Katherine Harris, Suhasini Iyer, Brett Jorgensen, Heather Ogana, Duy Pham, Payal Pratap, Udaya Rangaswamy, Ute Schellenberger, Nathan Trinklein, Harshad Ugamraj, Omid Vafa and Wim van Schooten

TeneoBio

Accelerating Drug Discovery Using The Transcriptic Robotic Cloud Laboratory

James C. Culver, Vanessa M. Biggers, Rhys A. Ormond, Yang Choo, Benjamin N. Miles, Yin He

Transcriptic, Inc.

LakePharma Protein Engineering Symposium

Friday, October 6th, 2017

So. San Francisco Conference Center

Online Registration:

Open through Wednesday, October 4, 2017

www.lakepharma.com/symposium

Symposium Organizing Committee:

Aaron Sato, Ph.D., Chief Scientific Officer, LakePharma

John "Lippy" Lippincott, Ph.D., VP of Antibody Discovery, LakePharma

Announcement:

Email symposium@lakepharma.com to submit abstracts for poster session (subject to availability)

Symposium Sponsors and Exhibitors:

